Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Levi Strauss & Co. (LEVI) Price & Performance

Davita IncTrade
Levi Strauss & Co.Trade

Price performance (Past 24H)

Key statistics

Davita Inc vs Levi Strauss & Co. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Levi Strauss & Co. trades at $19.01 (market cap $7.51B). The key difference: Davita Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.28% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Levi Strauss & Co. for 70 Days on average.

DVALEVI
Market Cap
$11.28B$7.51B
Volume
650,29417,462,954
Sector
HealthConsumer Cyclical
52-Week High
$240.96$25.53
52-Week Low
$103.87$17.92
Typical Hold Time
113 Days70 Days
Enterprise Value
$24.00B$9.06B
Dividend Yield
—3.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.

The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.

Levi Strauss & Co.

Levi Strauss (LEVI) trades at $19.05, down 7.21% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.84, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a '90s fashion revival benefiting the brand and the appointment of a new CFO effective November 2026. Cash flow trends have improved, with net cash flow turning positive in 2025 after prior volatility.

The outlook is positive given analyst consensus of a $27.80 price target and 79% buy ratings, though near-term price weakness and competitive pressures in apparel present risks. Earnings growth and direct-to-consumer expansion are key catalysts, but investors face execution risks and macroeconomic sensitivity.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
LEVI
52% Buy48% Sell
Avg holding period · 70 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Levi Strauss & Co.

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver

Read more on LEVI →